Table 1.
Baseline Demographics of Participants with Early Course Schizophrenia with Premorbid Sociality Scores
| Overall (N = 88) | CET (n = 52) | EST (n = 36) | ||
|---|---|---|---|---|
| Variable | M(SD)/N(%) | M(SD)/N(%) | M(SD)/N(%) | p c |
| Age | 24.95 (5.58) | 24.03 (4.18) | 26.28 (6.99) | .062 |
| Sex (% male) | 66 (75%) | 42 (81%) | 24 (67%) | .143 |
| Racial minority (%) | 37 (42%) | 21 (40%) | 16 (44%) | .827 |
| African American | 22 (25%) | 12 (23%) | 10 (28%) | - |
| White | 51 (58%) | 31 (60%) | 20 (55%) | - |
| Asian | 5 (6%) | 4 (7%) | 1 (3%) | - |
| Hispanic | 0 (0%) | 0 (0%) | 0 (0%) | - |
| Hawaiian/Pacific Islander | 1 (1%) | 1 (2%) | 0 (0%) | - |
| More than one race | 6 (7%) | 2 (4%) | 4 (11%) | - |
| Other | 3 (3%) | 2 (4%) | 1 (3%) | - |
| IQ | 107.91 (10.46) | 108.04 (9.63) | 107.72 (11.71) | .890 |
| Education (% some college) | 64 (73%) | 40 (77%) | 24 (67%) | .335 |
| Employment (% employed) | 26 (30%) | 13 (25%) | 13 (36%) | .343 |
| Illness Lengtha | 3.84 (2.31) | 3.86 (2.19) | 3.82 (2.51) | .940 |
| Schizophrenia Diagnosis (% with) | 70 (80%) | 43 (83%) | 27 (75%) | .427 |
| Substance Use Disorder History (% with) | 43 (49%) | 24 (46%) | 19 (53%) | .665 |
| Antipsychotic Dose (CPZ equivalent)b | 458.65 (342.93) | 466.96 (378.60) | 447.33 (292.29) | .796 |
| Antipsychotic Adherence (% adherent) | 63 (72%) | 39 (75%) | 24 (67%) | .473 |
Note. CET = Cognitive Enhancement Therapy, CPZ = Chlorpromazine, EST = Enriched Supportive Therapy
a
Based on a total sample of 87 with available data (CET: n = 52, EST: n = 35)
b
Based on a total sample of 85 with available data (CET: n = 49, EST: n = 36)
c
Results from independent samples t-tests or Fisher’s exact tests, two-tailed